Supports Chapter 20: Diabetes deceit
Aspirin should not be routinely prescribed to diabetics for the prevention of heart attack and stroke, say researchers.
The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) Trial involved 1,276 people with type 1 or type 2 diabetes who had no symptoms of coronary heart disease. Participants had either a daily 100 mg aspirin tablet plus antioxidant capsule, an aspirin tablet plus placebo capsule, a placebo tablet plus antioxidant capsule, or a placebo tablet plus placebo capsule.
Results showed that aspirin – whether taken alone or in combination with an antioxidant capsule – did not significantly reduce the risk of death from coronary heart disease or stroke, or non-fatal myocardial infarction or stroke.
The researchers conclude: “This trial does not provide evidence to support the use of aspirin or antioxidants in primary prevention of cardiovascular events and mortality.”
Let's face it, as Type-2 diabetes is so easily and quickly rectified merely by a change of diet, why take risks with any drugs?
Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840. doi: 10.1136/bmj.a1840